Grace Therapeutics, Inc. (GRCE)

In the past six months, Grace Therapeutics, Inc.'s stock price has been impacted by several key events. The company submitted an NDA to the FDA for GTx-104 for the treatment of aSAH around June 2025, which was accepted for review with a PDUFA target date of April 23, 2026, and secured approximately $4.0 million through common warrant exercises. The company announced its 2025 fiscal year-end results around June 2025, reporting a reduced net loss and a strong cash position, and provided business updates in November 2025, including second-quarter 2026 financial results. Grace Therapeutics participated in the 2025 BIO International Conference in June 2025 and the 16th Annual Craig-Hallum Alpha Select Conference in November 2025, and an abstract for presentation at the Society of Vascular and Interventional Neurology Annual Meeting was also accepted in November 2025. The results from the pivotal Phase 3 STRIVE-ON Safety Trial of GTx-104 in aSAH were presented at the 2025 Neurocritical Care Annual Meeting, meeting its primary endpoints and showing improved clinical outcomes compared to oral nimodipine.

Analysis of Grace Therapeutics, Inc. seasonal charts suggests a potential seasonal pattern in its stock performance, with a "Buy Date" of December 10 and a "Sell Date" of March 19 historically resulting in positive returns above the S&P 500 Total Return Index. The demand for its products, once commercialized, would likely be driven by medical necessity and patient populations rather than typical seasonal consumer trends. The demand for pharmaceutical products for life-threatening or chronic rare diseases is generally considered to be relatively inelastic and consistent throughout the year, independent of seasonal variations.

Grace Therapeutics, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing pharmaceutical products for rare and orphan diseases. The company operates within the Healthcare sector, specifically in the Biotechnology and Drugs industry, and was formerly known as Acasti Pharma Inc., changing its name in October 2024. Its primary product candidates include GTX-104, an intravenous infusion for aneurysmal Subarachnoid Hemorrhage (aSAH) with Orphan Drug Designation from the FDA; GTX-102, an oral mucosal spray of betamethasone for neurological symptoms associated with Ataxia-Telangiectasia (A-T); and GTX-101, a topical bioadhesive film-forming polymer for postherpetic neuralgia (PHN) pain.

Grace Therapeutics, Inc. is headquartered in Princeton, New Jersey, United States. The company develops and commercializes pharmaceutical products for rare and orphan diseases in Canada. Its lead clinical assets have been granted Orphan Drug Designation by the FDA, providing market exclusivity in the United States.

Grace Therapeutics, Inc. positions itself as a pioneering biopharmaceutical company dedicated to developing innovative therapies for debilitating diseases, particularly rare genetic disorders and complex diseases with unmet medical needs. The company emphasizes its commitment to scientific excellence, patient advocacy, and ethical business practices. Its lead clinical assets have been granted Orphan Drug Designation by the FDA, which can enhance its reputation in the specialized field of rare diseases. The company's rebranding from Acasti Pharma Inc. to Grace Therapeutics, Inc. in October 2024 was intended to reconnect with its foundational roots in scientific innovation and reflect its extensive scientific heritage.

Grace Therapeutics, Inc. has a mix of institutional and individual owners. Institutional investors own 6.08% of the stock, with major shareholders including AIGH Capital Management LLC, Nantahala Capital Management LLC, ADAR1 Capital Management LLC, Stonepine Capital Management LLC, The Vanguard Group, Inc., and Bank of America Corporation. Significant individual and insider owners include Grace 2018 Irrevocable Trust Rajitha, holding 33.19% of shares, Santosh Kottayil, George Kottayil, and William A. Haseltine.